(duplicate) SPLDv3
Research type
Research Database
Full title
Secondary and Primary care Longitudinal Database (SPLD)
IRAS ID
138054
Contact name
Michael Sanvoisin
Contact email
Research summary
(duplicate) SPLDv3
REC name
South West - Central Bristol Research Ethics Committee
REC reference
09/H0106/19+5
Date of REC Opinion
29 Nov 2013
REC opinion
Favourable Opinion
Data collection arrangements
This database combines information on hospital drug usage, hospital activity (HES database) and primary care practices (via the Clinical Practice Research Datalink (CPRD) database). The combination of these data sources creates insight into the interaction in both secondary and primary care between disease, treatment and prescribing.
No identifiable data will be contained within the database. The pseudonymised data will contain no information on the location of the Hospital Trust, or practice, at which patients are registered. Pseudonyms used cannot be related to any identifier.
The pseudonymised data will be held by IMS in a location with an ISO27001 information security certificate. Access to the data is restricted to employees or contractors of IMS, or CPRD, is strictly controlled and audited, and those with access must also sign a stringent access agreement.
All studies using the linked data HES- prescribing data must first be submitted to IMS’ Independent Scientific and Ethics Advisory Committee (ISEAC). All studies using the linked HES-hospital prescribing-CPRD data must first be submitted to CPRD’s Independent Scientific Advisory Committee (ISAC).
IMS and CPRD will only release aggregated or tabulated data that has also been subjected to the normal HES protocol rules for release (e.g. small numbers).
Research programme
The community supported by this database include the Pharmaceutical Industry, NICE, MHRA and Department of Health. Access is not restricted to any particular group. The types of research, with examples, that will be carried out include: o Pharmacovigilance – for example; enabling estimates of exposure to drugs in hospital for the first time and enabling assessment of risk following off label use or specific issues affecting drug use in secondary care o Drug utilisation – for example; enabling more granular analysis of the uptake of NICE guidance and other pharmaceuticals , improving the ability of Trusts and managers to reduce hospital acquired infections and drug usage in relation to the Payments by Results (PbR) tariff o Health economics and outcomes research – for example; enabling a more informed analysis of treatment outcomes leading to better knowledge and improved clinical decision making
Research database title
(duplicate) SPLDv3
Establishment organisation
IMS HEALTH UK Ltd
Establishment organisation address
210 Pentonville Road
London
N1 9JY